TriangleDISEASE & TREATMENT SETTING
Oropharyngeal Cancer
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Oropharyngeal Cancer
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- unresolved
- derivation note
- Derived from NCI topic(s): Oropharyngeal Cancer. Strongest NCIt resolution: ambiguous. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
5 more-specific settings
Study evidence for this setting
Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Robotic Assisted Surgery in Upper Aerodigestive Tract Surgery
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
F-18 Fluorothymidine PET Imaging for Early Evaluation of Response to Therapy in Head & Neck Cancer Patients
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-oropharyngeal-cancer
- binding id
- ncit-C7398
- source collection
- ncit-concept
- source key
- C7398
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- release id
- clinical-indications-draft-1
- disease state id
- ds-oropharyngeal-cancer
- binding id
- ncit-C9105
- source collection
- ncit-concept
- source key
- C9105
- source excerpt
- Source null
- match status
- ambiguous
- match note
- Resolution status: ambiguous.
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice